FreeBioList

Catalysts / COGT

Cogent Biosciences (COGT) catalysts

Upcoming FDA decisions and readouts we track for Cogent Biosciences, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 2 Rows last checked — 11 Sep 2026

FreeBioList tracks 2 upcoming catalysts for Cogent Biosciences (COGT, listed on Nasdaq). Both concern Bezuclastinib (Gastrointestinal stromal tumour (GIST); Non-advanced systemic mastocytosis).

First on the list: the PDUFA date for Bezuclastinib (Gastrointestinal stromal tumour (GIST)), dated 30 Nov 2026. By stage, the upcoming rows are 2 PDUFA dates.

Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.

Background reading: What a PDUFA date is, and why the FDA doesn't publish them.

Ticker
COGT
Next catalyst
30 Nov 2026
Type
PDUFA date
Listed options
Yes
Company ▾ Drug ▾ Effect / indication Next catalyst ▾ Phase / type ▾ Status ▾ Source Options
Cogent Biosciences COGT · Nasdaq Bezuclastinib Gastrointestinal stromal tumour (GIST) 30 Nov 2026
in 54d		 PDUFA date Verified 8-K exhibit 99.1 ↗ Yes
Cogent Biosciences COGT · Nasdaq Bezuclastinib Non-advanced systemic mastocytosis 30 Dec 2026
in 84d		 PDUFA date Verified 8-K exhibit 99.1 ↗ Yes

Also due in Q4 2026